With a commitment to quality, scientific excellence and exceptional customer experiences, Patheon is the world's leading provider of contract pharmaceutical development services and commercial manufacturing.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Patheon specialises in pharmaceutical development and manufacturing services.
Patheon provides an integrated and customizable range of active pharmaceutical ingredients (API) and finished drug product services, including formulation development, clinical and commercial-scale manufacturing, packaging, and lifecycle management.
The company’s services address small and large molecule biological drugs.
Patheon is an end-to-end integrated provider, which combines scientific and regulatory expertise and specialised capabilities. This provides clients with a single outsourced provider to address complex development and manufacturing challenges.
Patheon specialises in leading product development services and commercial-scale product manufacturing.
Patheon transforms the pharmaceutical supply chain model with innovative, flexible, and customised end-to-end development, as well as manufacturing solutions that reduce complexity and shorten time-to-market.
Clients gain access to a wide range of drug substances, pharmaceutical development, and drug product solutions for large and small molecules, including an array of oral solid, sterile, and softgel dosage forms.
This provides flexibility to choose the most appropriate chemistry, manufacturing, and controls (CMC) technologies with the confidence that the programme will be delivered on time.
The company employs new business models to help clients simplify their supply chain management activities in an increasingly complex drug development industry.
Patheon is organized into three distinct business units, drug substance services (DSS), pharmaceutical development services (PDS), and drug product services (DPS).
DSS is one of the top three outsourced manufacturers of highly complex biological drug substance produced in four biological API facilities. These sites are positioned to serve 70% of the market.
Patheon provides complex small molecule APIs and flexible outsourced manufacturing solutions for large molecule biologic APIs from early development through to commercial-scale production.
PDS Patheon is a leading global provider of formulation services. The company’s capabilities span the full breadth of advanced scientific services, including discovery, regulatory approval and formulation development across 40 dosage forms, as well as analytical services and life-cycle management.
DPS Patheon has developed and manufactured 20% of the top 100 drugs and 75% of the dosage forms on the market over the past decade.
Patheon has 8,700 employees, including more than 600 scientists in 25 locations in Europe, North America, Australia, and Asia.
The company has provided development and manufacturing services for approximately 400 clients for more than 700 products and molecules.
Through Patheon’s integrated global network of facilities, clients needs are met, which includes expertise to pharmaceutical, biotechnology and specialty pharmaceutical companies. This expertise helps clients bring drug candidates, including pre-clinical stages such as clinical trials and commercial supply.
Patheon provides a comprehensive suite of capabilities that addresses 75% of dosage forms with expertise and specialised capacity in high-potency, controlled substances, low-solubility, sterile, modified release, and softgel technologies.
Patheon OneSource is an end-to-end development product that is simple to use, quick, and high-quality.
Patheon offers four specific flexible manufacturing options which are the dedicated asset model, fractional ownership model, flexible network access and the ‘condominium model.’
The company provides pharmaceutical and biotechnology companies with direct access to the expertise, quality, and full range of small or large molecule drug substance and solid and sterile dosage forms including:
Improving the bioavailability of poorly soluble new chemical entities is a leading challenge in drug development. Parallel screening is a cost-effective concept for selecting a suitable drug delivery system to enhance the chance of achieving the bioavailability target in the clinic.
The challenge of taking a drug candidate from discovery through to market should not be underestimated, as there can be many hurdles to face along the path.
Early stage manufacturers of oral solid dosage forms need to be fast and flexible to generate development pathways that can cope with variable API characteristics, as well as highly potent molecules.
With the advent of combinatorial chemistry and high throughput screening, the number of poorly water soluble drug candidates has dramatically increased. The "drugability" of new chemical entities (NCEs) and life-cycle management of marketed pharmaceutical products are becoming more challenging.
Approval of new drug products that treat unmet medical needs held steady or declined over the last decade.
For a drug product to exert its therapeutic effect, it must be soluble in an aqueous environment. This ensures that the active pharmaceutical ingredient (API) will provide sufficient concentration to induce gastrointestinal (GI) tract absorption.
The proportion of poorly soluble drug compounds in the development pipeline is on the rise, with 70% to 90% of current pipeline drugs falling in the two low-solubility classes of the biopharmaceutical classification system.
Controlled-release drug delivery systems can be broadly classified as either single-unit dosage forms or multiple-unit dosage forms.
Patheon is one of the largest contract drug development and manufacturing service providers in the world. To meet the in
Canadian contract drug maker Patheon, completed the expansion of its Toronto manufacturing facility in April 2009, two m
Patheon has made an initial public offering of 30,487,805 of its ordinary shares
Patheon has announced it has signed a manufacturing agreement with Amgen, one of the world's leading biotechnology companies, headquartered in Thousand Oaks, CA.
Patheon has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal's innovative abuse deterrent formulation technology INTAC.
The complexity of drug product supply chains has increased over the last few years mainly due to the development of more complex chemical molecules with more synthesis steps, increasing suppliers and geographies in the chain, and reduced average production volumes.
Experts from Patheon will present on a range of industry topics at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition from 25-29 October in Orlando.
Patheon will be attending the 26th Annual CPhI ICSE Worldwide conference from 13 - 15 October in Madrid.
Patheon has unveiled its new brand identity, reflecting the company's leadership position in the pharmaceutical services industry, and the difference it makes in the lives of patients.
LIVIA Group has entered an agreement to acquire the Capua manufacturing facility and associated employees from Patheon.
Patheon has entered a development contract with Inhibrx, a biologic immunotherapeutic company focused on high, unmet medical needs in oncology, infectious disease and inflammatory conditions.
Patheon will showcase ways to accelerate biologic process development and funding options for biopharmaceutical programmes at the BIO International Convention in Philadelphia from 16-17 June.
Patheon has announced that Dr Marshall Crew, vice-president, global PDS scientific excellence, has been named one of the top 100 most influential people in drug development and manufacturing by the publication the Medicine Maker.
Analytical development experts will address questions about regulatory requirements, stability and shipping studies in a complimentary webinar in May, sponsored by Patheon.
Patheon is investing more than $3 million to expand its Greenville, North Carolina site's stability testing capabilities.
Patheon will showcase its development and manufacturing services and integrated offerings at INTERPHEX in New York from Tuesday 21 to Thursday 23 April.
Patheon has closed the acquisition of IRIX Pharmaceuticals, a company that specialises in making difficult to manufacture active pharmaceutical ingredients (API) for drugs from early and late development, through to commercial launch.
Patheon will participate at DCAT Week 2015 in New York from 16-19 March.
Patheon has reached a definitive agreement to acquire Agere Pharmaceuticals, headquartered in Bend, Oregon, that specialises in improving absorption rate of medications (bioavailability).
Patheon has announced it has reached a definitive agreement to acquire IRIX Pharmaceuticals.
Patheon has added a new filling technology that significantly reduces the time needed for formulation development and stability testing at its facility in Milton Park, UK.
An expert from Patheon will highlight the company's strategy for delivering exceptional customer experience through its integrated offerings at the Seventh Annual Global Biomanufacturing Summit.
DPx Holdings BV has announced that CEO James C Mullen will present an overview of the company and its contract development and commercial manufacturing (CDMO) business Patheon, at the 33rd Annual JP Morgan Healthcare Conference.
Patheon has announced Tom Sellig will be senior-vice president of global sales and Christopher Tama will be the new senior vice-president of global marketing.
Patheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from Tuesday 7 October to Thursday 9 October in Paris Nord Villepinte, France.
Patheon is to attend a number of forthcoming pharmaceutical industry events and host informative webminars.
DPx Holdings BV has announced that it has reached a definitive agreement to buy all the shares of Gallus BioPharmaceuticals, a leading contract manufacturing company specialising in biologics and current portfolio company of Ridgemont Equity Partners.
Patheon, the pharmaceutical services business owned by DPx Holdings B.V, announced the launch of its updated programme Quick to Clinic™, making it the only CDMO to offer customers an accelerated 12-week clinical trial material programme with stability data, with a variety of flexible dosage forms.
Patheon gives global pharmaceutical, biotechnology and specialty pharmaceutical companies access to the resources and expertise to bring drug candidates from preclinical stages through clinical trials to commercial supply.
Patheon has joined with DSM Pharmaceutical Products to form businesses with an unmatched breadth of capabilities and expertise in API, biologics, development and commercial-scale manufacturing.
This week, Patheon has been showcasing the company's fully integrated early development services at the 41st Annual Meeting & Exposition of the Controlled Release Society (CRS) at The Hilton Chicago in Chicago, Illinois, US.
DPx Holdings BV is launching a new, US-wide operational excellence programme, called Driving Performance eXponentially (DPx).
DPx Holdings BV (DPX) has donated a total of $110,000 to more than 20 hospitals and good causes around the world.
Patheon has launched the SoluPath Flex™, providing the pharmaceutical industry with a new low solubility solution.
Patheon is sharing a series of papers on Pharmaceutical-technology.com, targeting the early phase pharmaceutical development process.
Patheon Inc is to launch the company's capabilities at FCE Pharma in Sao Paulo, Brazil, 12-14 May 2014.
Patheon personnel and scientific experts will be available to meet at the CPhI/ICSE - Japan conference in Tokyo from 9-11 April to discuss how Patheon can actively support pharmaceutical and biotech companies achieve their key development and manufacturing goals.
Patheon has recently received FDA approval for its Bourgoin, France site to begin manufacturing and selling drugs to the US market.
Patheon is to attend the 2014 DCAT Week from 10-13 March.
Patheon is to specialise in high-potency at the company's Milton Park, UK, facility. Investment in early development capabilities in Europe means increased capacity for handling highly potent compounds in the early pharmaceutical development phases in the UK and then feeding into the later stage and commercialisation capabilities at a site in Bourgoin, France.
Patheon is increasing solid dose capabilities at its European sites, with the latest investments being made at its UK facility, Milton Park.
JLL Partners and Royal DSM have today announced the creation of a new company, which will be a leading global contract development and manufacturing organisation (CDMO) for the pharmaceutical industry with anticipated sales of around $2bn.
Patheon Inc is to attend Nuova Ompi - Stevanato Group's Innovation Day 2013 at the West Grand Frankfurt Hotel in Frankfurt, Germany, this week.
Patheon will showcase its offerings, including non-sterile, sterile and softgel dose forms at CPhI/ICSE in Messe Frankfurt, Germany, 22-24 October.
Patheon has released a free white paper entitled 'Formulating and Producing Tablets Containing Large, Coated Multiparticulates'.
The PharmaVOICE 100 award represents a broad cross section of industry sectors.
Patheon is a leading provider of contract pharmaceutical development services and commercial manufacturing. Patheon has three white papers available for download free of charge from Pharmaceutical Technology.
Patheon, a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that it will be hosting a complimentary seminar entitled "Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success".
Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, is hosting a complimentary, half-day seminar entitled "Product Enhancement through Complex Dosage Forms: Adding Value to Products' Lifecycle Management" on June 18, 2013 at the MassBio Headquarters in Cambridge, Massachusetts.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its high potency capabilities at the 2013 BIO International Convention in Chicago, Illinois on April 22 - 25, 2013, as well as at INTERPHEX 2013 in New York City on April 23 - 25, 2013.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will be exhibiting and presenting at the 2013 Global Formulation and Drug Delivery Summit in Amsterdam, the Netherlands.
Internationally renowned pharmaceutical contract developer Patheon has released a preview of its online seminar, entitled 'Getting Your Drug through Phase I Early Development Effectively', on Pharmaceutical Technology.
Patheon, a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced plans for additional investment in its Milton Park facility.
Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results for fiscal 2012.
Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it has completed its acquisition of Banner Pharmacaps (Banner), a specialty pharmaceutical business dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.
All pharmaceutical products have unique manufacturing challenges and the available options need to precisely meet these needs.
Patheon OneSource speeds up the development timelines of large and small molecule discoveries.
